Aptamer which selectively binds to ERBB2 receptor and uses thereof
US9309515B2 · kind B2 · utility
1Cited by
1References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 10, 2011 |
| Grant date | Apr 12, 2016 |
| Priority date | — |
| Expiry date | Aug 10, 2031 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/91205
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are a DNA aptamer specifically binding to the Her2 (ERBB2) receptor involved in the onset of breast cancer, a composition for the suppression of cancer metastasis comprising the same as an active ingredient, and a composition for the diagnosis of cancer comprising the same as an active ingredient. Due to its binding mechanism being different from that of the conventional antibody, the aptamer can be effectively used for suppressing cancer metastasis and diagnosing cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.